Your session is about to expire
← Back to Search
Azacitidine + Gemtuzumab for Acute Myeloid Leukemia
Study Summary
This trial is studying azacitidine and gemtuzumab ozogamicin to treat older patients with previously untreated acute myeloid leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My leukemia is either acute promyelocytic or in a blastic phase of chronic myelogenous.I am not allergic to azacitidine, mannitol, hydroxyurea, or gemtuzumab ozogamicin.I have been diagnosed with a specific type of leukemia, not including acute promyelocytic leukemia or blastic phase CML.I can take care of myself but may not be able to do heavy physical work.I haven't had chemotherapy for acute leukemia, except possibly hydroxyurea.I've had intense chemotherapy or stem cell support for myelodysplastic syndrome.I have been treated with azacitidine, decitabine, or gemtuzumab ozogamicin.My cancer has spread to my brain or spinal cord.My heart pumps well and I haven't had heart failure in the last 56 days.My side effects from initial cancer treatment are mild or gone.My bilirubin levels are within twice the normal limit, not due to liver infiltration by AML.My liver function tests are within normal limits.I have had cancer before, but it fits the exceptions.My cancer has not spread to my brain or spinal cord.
- Group 1: Treatment (azacitidine, gemtuzumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies remaining for participants of this clinical trial?
"At the present time, this experiment is not recruiting participants. It was originally posted on December 1st 2008 and then edited most recently in October 15th 2022. For those considering other trials, there are currently 1534 studies actively seeking patients with leukemia, myelomonocytic acute and 197 clinical trials using Azacitidine that are accepting applications."
How many participants are engaged in this research endeavor?
"This clinical trial has ceased its recruitment process. The initial posting was on December 1st 2008 and the last update occured October 15th 2022. If you are search for other trials, there is a list of 1534 studies recruiting patients with leukemia or myelomonocytic acute leukaemia, as well as 197 studies actively seeking participants to use Azacitidine."
What medical applications commonly employ Azacitidine?
"Azacitidine is a preferred choice for induction chemotherapy. It can also provide relief from refractory anemias, leukemia, myelocytic and acute multilineage dysplasia."
What other explorations have been undertaken to explore the potential of Azacitidine?
"Azacitidine's first clinical trials were conducted in 2006 at the Chinese University of Hong Kong-Prince of Wales Hospital. As of now, a total 184 studies have been concluded and 197 are still ongoing - with many taking place within Livonia, Michigan."
Has the Federal Drug Administration sanctioned Azacitidine?
"The safety of Azacitidine is assigned a rating of 2 since it has only undergone Phase 2 trials, demonstrating some degree of security but no efficacy data."
How many centers are currently administering this study?
"This medical study has 100 participants, including those from Saint Mary Mercy Hospital in Livonia, Lake Huron Medical Center in Port Huron and Research Medical Center in Kansas City."
Share this study with friends
Copy Link
Messenger